SC 51089 free base is a selective antagonist of prostaglandin E 2 EP1 receptor , with K i s of 1.3, 11.2, 17.5, and 61.1 μM for EP1 , TP , EP3 , and FP receptors , respectively. SC 51089 free base exhibits neuroprotective activity In Vitro SC 51089 free base (5 μM; 24 h) attenuates prostaglandin E2 (PGE2)-induced the death of neuronal cells exposed to t-BuOOH. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SC 51089 free base (40 μg/kg; infused i.p. for 28 d) ameliorates motor coordination and balance dysfunction and rescues long-term memory deficit in R6/1 mouse model of HD. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: R6/1 mouse model of Huntington's disease (HD), from 13 to 18 weeks of ageDosage: 40 μg/kg/day Administration: Infused i.p. at a rate of 0.11 μL/h during 28 days by osmotic mini-pump system Result: Ameliorated motor coordination and balance dysfunction. Rescued long-term memory deficit. Improved the expression of specific synaptic markers. Reduced the number of huntingtin nuclear inclusions in the striatum and hippocampus. Form:Solid IC50& Target:EP1 1.3 μM (Ki) TP 11.2 μM (Ki) EP3 17.5 μM (Ki) FP 61.1 μM (Ki)